ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Cell > OX40 Ligand > CHEK-ATP054

HEK293/Human OX40 Ligand / TNFSF4 Stable Cell Line

  • Description
    HEK293/Human OX40 Ligand / TNFSF4 Stable Cell Line
  • Application

    Binding assay by FACS and cell based ELISA

  • Growth Properties
    Adherent
  • Selection Marker
    Puromycin (10 μg/mL)
  • Culture Medium
    DMEM medium + 10% FBS
  • Freeze Medium
    10% DMSO + 90% FBS
  • Quantity
    1 vial contains at least 5x10^6 cells in 1 ml of 10% DMSO in FBS.
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Bioactivity
 OX40 Ligand FACS

FACS assay shows that Biotinylated Human OX40, Avitag,His Tag (TN4-H82E4) can bind to HEK293/Human OX40 Ligand / TNFSF4 Stable Cell Line (CHEK-ATP054). HEK293/Human OX40 Ligand / TNFSF4 Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).

Please contact us if you are interested in related cell pool service.

  • Background
    Tumor necrosis factor ligand superfamily member 4 (TNFSF4) is also known as glycoprotein Gp34, OX40 ligand (OX40L), TAX transcriptionally-activated glycoprotein 1 and CD252, which belongs to the tumor necrosis factor family. TNFSF4 is the ligand for CD134 and is expressed on such cells as DC2s (a subtype of dendritic cells) enabling amplification of Th2 cell differentiation. The interaction of TNFSF4-TNFSF4 is involved in the pathogenesis of multiple autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), carotid artery disease and cancer. Furthermore, similar to other TNF superfamily members, membrane-bound OX40 Ligand (TNFSF4) exists as a homotrimer. Human TNFSF4 shares 46% amino acid sequence identity with its mouse counterpart.
  • License Disclosure
    This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
  • Clinical and Translational Updates

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : 980,000

プロモーション&展示



医薬品開発状況

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:7 Details
  • Latest Research Phase:Phase 3 Clinical

データシート&ドキュメンテーション

関連製品一覧

新製品

お問い合わせ&コメント

This web search service is supported by Google Inc.

totopphone